Brief: Genmab Says To Submit SBLA To FDA For Ecoritamab In 2025
02/05/2025 01:17
May 1 (Reuters) - Genmab A/S GMAB.CO: GENMAB TO SUBMIT SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) TO U.S. FOOD AND DRUG ADMINISTRATION FOR EPCORITAMAB PLUS RITUXIMAB AND LENALIDOMIDE (R2) IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) GENMAB A/S - TO SUBMIT SBLA TO FDA FOR EPCORITAMAB IN 2025 Source text: ID:nGNX6Kzzn8 Further company coverage: GMAB.CO ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Genmab A/S
See all newsBrief: Genmab Says Orbis Investment Management Holds 4.99% Of Genmab Voting Rights As Of June 12
Brief: Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Brief: Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination
Brief: Genmab Says Orbis Investment Management Limited Holds 5.08% Of Genmab A/S As Of May 8, 2026
Genmab falls after 'uneventful' Q1, profit miss